Embracing China’s brave new pharmaceutical world

| November 27, 2017

article image
Sales of pharmaceuticals in China are already the third highest in the world, and China is likely to become the world’s second-largest drug market within the next year. Multinational pharmaceutical corporations cannot afford to underperform in China if they want to achieve global prominence.

Spotlight

Avara Pharmaceutical Services

Home Avara Pharmaceutical Services is a state of the art Contract Manufacturing Organization. We focus our efforts on Quality, Compliance, Customer Service, and delivering on time and in-full. We have a senior leadership that have managed manufacturing infrastructures worldwide. Avara Pharmaceutical Services was founded by a team of industry veterans who, through personal experience, understand both sides of the contract manufacturing market. Our team is fully aware of customers’ expectations. Therefore, we built a CDMO that provides exceptional service and a world-class experience by delivering on our commitments. These commitments include delivering to scope, schedule, meeting regulatory requirements and quality standards, all at an agreed and fair price.

OTHER ARTICLES

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | April 17, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 4, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

Pricing of drugs – at what cost?

Article | February 27, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More

Top Specialty Pharmacy Therapy Areas

Article | March 16, 2020

Accelerated by advancements in cancer treatments and a growing emphasis on personalized and precision medicine, specialty pharmacy represents a rapidly growing sector within the healthcare industry. In fact, the market is projected to grow to $500 billion by the end of this year—up from $200 billion in total U.S. specialty drug spending in 2017. Industry growth of this magnitude creates challenges for those looking to understand and penetrate the market. It can be difficult, after all, to maintain updated information about high-priority drug therapy areas or facility affiliations in a market that’s constantly changing.

Read More

Spotlight

Avara Pharmaceutical Services

Home Avara Pharmaceutical Services is a state of the art Contract Manufacturing Organization. We focus our efforts on Quality, Compliance, Customer Service, and delivering on time and in-full. We have a senior leadership that have managed manufacturing infrastructures worldwide. Avara Pharmaceutical Services was founded by a team of industry veterans who, through personal experience, understand both sides of the contract manufacturing market. Our team is fully aware of customers’ expectations. Therefore, we built a CDMO that provides exceptional service and a world-class experience by delivering on our commitments. These commitments include delivering to scope, schedule, meeting regulatory requirements and quality standards, all at an agreed and fair price.

Events